P1095: TREATMENT ATTRIBUTES FOR 3RD LINE FOLLICULAR LYMPHOMA TREATMENT DECISION-MAKING: PHYSICIAN PERSPECTIVES FROM A SURVEY ACROSS WESTERN EUROPE AND THE UNITED STATES

• P. C. Johnson,
• A. Bailey,
• N. Milloy,
• E. Clayton,
• R. G. Quek,
• Q. Ma

Affiliations

P. C. Johnson

1 Department of Medicine, Division of Hematology & Oncology, Massachusetts General Hospital Cancer Center & Harvard Medical School, Boston, United States of America

A. Bailey

2 Oncology, Adelphi Real World, Bollington, United Kingdom

N. Milloy

2 Oncology, Adelphi Real World, Bollington, United Kingdom

E. Clayton

2 Oncology, Adelphi Real World, Bollington, United Kingdom

R. G. Quek

3 Health Economics & Outcomes Research, Regeneron Pharmaceuticals Inc., Sleepy Hollow, United States of America

Q. Ma

3 Health Economics & Outcomes Research, Regeneron Pharmaceuticals Inc., Sleepy Hollow, United States of America